TARS2: A Potential Drug Target for Psychiatric Disorders (G80222)

Target Name: TARS2

NCBI ID: G80222

TARS2

TARS2: A Potential Drug Target for Psychiatric Disorders

TARS2 (thrRS) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Tars family of proteins, which are involved in various cellular processes, including cell signaling and structural support. TARS2 is unique among its family members because it is a receptor for small molecules, such as hormones and neurotransmitters.

Recent studies have suggested that TARS2 may be a drug target or biomarker for various psychiatric and neurological disorders, including depression, anxiety, and neurodegenerative diseases. This is because TARS2 has been shown to play a role in the regulation of mood and emotion, as well as the maintenance of brain structure and function.

One of the key factors that makes TARS2 an attractive drug target is its role in the regulation of neurotransmitter release from neurons. Neurons release neurotransmitters, such as dopamine and serotonin, in response to the presence of certain molecules, such as food, sex, or other environmental stimuli. The release of these neurotransmitters is critical for the proper functioning of the brain and the body. However, if the release of these molecules is imrupted, it can lead to various psychiatric and neurological disorders.

TARS2 has been shown to play a role in the regulation of neurotransmitter release from neurons by interacting with a protein called TrkB. TrkB is a transmembrane protein that is involved in the intracellular signaling of various neurotransmitters, including dopamine, serotonin, and GABA. TARS2 has been shown to interact with TrkB and to modulate its activity. This interaction between TARS2 and TrkB suggests that TARS2 may be a useful drug target for the treatment of psychiatric and neurological disorders associated with disruptions in neurotransmitter release.

In addition to its role in neurotransmitter release, TARS2 has also been shown to be involved in the regulation of brain structure and function. TARS2 is a member of the Tars family of proteins, which are involved in the regulation of cellular processes that are critical for brain development and maintenance. TARS2 has been shown to be involved in the regulation of cell proliferation, migration, and the formation of neural networks.

TARS2 has also been shown to play a role in the regulation of pain perception. Pain perception is a critical aspect of the body's immune system, and is involved in the regulation of tissue repair and regeneration. TARS2 has been shown to be involved in the regulation of pain perception by interacting with a protein called Nav1. Nav1 is a protein that is involved in the regulation of pain perception, and has been shown to be regulated by TARS2.

In conclusion, TARS2 is a protein that has been shown to play a role in the regulation of various cellular processes that are critical for the functioning of the brain and the body. Its unique ability to interact with neurotransmitters and to regulate brain structure and function make it an attractive drug target for the treatment of psychiatric and neurological disorders. Further research is needed to fully understand the role of TARS2 in the regulation of mood and emotion, as well as the regulation of pain perception.

Protein Name: Threonyl-tRNA Synthetase 2, Mitochondrial

Functions: Catalyzes the attachment of threonine to tRNA(Thr) in a two-step reaction: threonine is first activated by ATP to form Thr-AMP and then transferred to the acceptor end of tRNA(Thr). Also edits incorrectly charged tRNA(Thr) via its editing domain

The "TARS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TARS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets